Topic Archives: Esperion Therapeutics (ESPR)

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. You can see all of his articles archived here. Enjoy!] CoLucid Pharmaceuticals, which recently moved from Durham, NC, to Cambridge, MA, plans an initial public offering. Recent news suggests the […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]

Comments

  • Travis Johnson, Stock Gumshoe
  • Avatar

    Lashmet was plugging Esperion Therapeutics, Inc. (ESPR) not too long ago, and that has been a real dog....

  • Avatar

    I have watched ESPR for a while now with mixed assessment. What do the rest of you think? I bought CRSP and Editas, as...

  • Avatar

    Unfortunate for you if you don't start buying in phases here.....this is a $100 stock in the next 24 mos....

  • Avatar

    Earlier this year (or maybe it was late last year), I listened to a Stansberry infomercial where Steve Sjuggerud gave hi...

  • Avatar

    XLNX and ESPR. Let's follow. ESPR's earning will be out shortly....

  • Avatar

    Blanco's projection for Esperion (ESPR) may have been overblown, but 2020 should be a pivotal year for the company as th...

  • Avatar
  • Avatar

    The concept that any pre-commercial biotech will cure your retirement woes is ridiculous. That said, as a professional i...

  • SoGiAm

    $ESPR > Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program of Bempedoic Acid and Positive Cumul...

  • Avatar

    The drug from Esperion (Bempedoic Acid) has a number of things going for it: it inhibits cholesterol synthesis at an ear...

  • Travis Johnson, Stock Gumshoe

    I suspect they did that because it’s easier and cheaper to get approval for conditions where current therapies haven...

  • Avatar

    #Esperion (#ESPR) It seems to me that most people on anti-chlolesteral drugs are fairly healthy. Why would Esperion all...

  • Michael Jorrin,

    Since blood pressure and cholesterol-lowering drugs have become cheap and common, heart disease mortality has plummeted,...

  • Avatar

    I sold my ESPR in early 2015 with a tidy 30% profit. I dodged a bullet as it soon dropped a lot. Didn't repurchase at ...

  • Avatar

    Esperion to The Medicines Company? Their studies have shown (to date) even better results than approved PSK9 drugs, have...

  • Avatar

    Too risky for me. Too many deaths in trials. Probably not caused by the drug, as some of the patients were very sick. Wo...

  • Travis Johnson, Stock Gumshoe

    I think you're right, we covered that one here: https://www.stockgumshoe.com/reviews/stansberry-venture/stansberry-ventu...

  • Avatar

    #ESPR long I just had to say that this comment"You’re either smart and long $ESPR, or you’re a blithering idiot" ma...

  • Avatar

    $ESPR, no real doubt here, 10% of my overall portfolio is parked in it. Was looking to add another 10%, but the price s...

  • DrKSSMDPhD

    Psychological obsession often declares its own extinction by the expression of bursts of compulsion in which the obsessi...

  • Avatar

    $ESPR, long 2x, I think they have 1 Phase 3 readout this quarter, and 3 other Phase 3 readouts by June. As long as they...

  • Avatar

    $ESPR Credit Suisse’s new analyst, Martin Auster, started coverage of eight biotech stocks with outperform rating, ...

  • Avatar

    $ESPR full position. I wonder who would buy Esperion? Presumably one of the very big boys, but wouldn’t that suggest a...

  • Avatar

    4ESPR LONG Esperion initiated with an Outperform at Credit Suisse Credit Suisse analyst Martin Auster started...

  • Avatar

    $ ESPR LONG Esperion Therapeutics target raised to $88 at UBS reflecting higher peak sales ests for bempedoic aci...

  • Avatar

    $ESPR LONG theflyonthewall.com: Esperion price target raised to $105 from $70 at Stifel Stifel analyst Alex Sch...

  • Avatar

    $ESPR -Me too: twice with statin-caused musculature problems - first time after many years on Lipitor; two years off, th...

  • Avatar

    Fred, From past KSS discussions, it is a given that $ESPR is unique and should be profitable and bound for success. Th...

  • Avatar

    #ESPR LONG From J.P. Morgan Nuetral disclosures. J.P. Morgan does and seeks to do business with companies cover...

  • Avatar

    Bempedoic Acid: A Statin Equivalent for the Statin Intolerant $ESPR The statin class provided a major breakthrough f...

  • Avatar

    $ESPR ++ Acute Coronary Syndrome Market in 2017 and Beyond 0 Shares Acute coronary syndrome (ACS) refers to a sp...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info